BioSpace News Archive

Regeneron Pharmaceuticals, Inc. announced the first presentations of positive detailed results from two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens, compared to EYLEA® Injection, in patients with diabetic macular edema and wet age-related macular degeneration.

Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration has approved LYTGOBI® tablets for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements.

Apellis Pharmaceuticals, Inc. announced new data from the 24-month Phase 3 OAKS study of pegcetacoplan, an investigational targeted C3 therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration.

In an important proof-of-concept study in the field of xenotransplantation, experts at Cincinnati Children’s have demonstrated that embryos from interspecies chimeras can be used as bioreactors to produce bone marrow cells needed for transplant procedures to treat leukemias and other blood disorders.

Sarepta Therapeutics, Inc. granted equity awards on September 30, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 43 individuals hired by Sarepta in September 2022.

Carestream Health announced that it has successfully completed its recapitalization process and emerged from Chapter 11.

Adicet Bio, Inc. announced it granted inducement awards on September 30, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to four individuals hired by Adicet in September 2022.

Aptorum Group Limited provided a business update and announced financial results for the six months ended June 30, 2022.